TrialScientific reports2024

A randomized double-blind placebo-controlled trial of an inhibitor of plasminogen activator inhibitor-1 (TM5614) in mild to moderate COVID-19.

Toyohiro Hirai et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.